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ABSTRACT
This article summarizes the recent activity of the International Stem Cell Banking Initiative (ISCBI)
held at the California Institute for Regenerative Medicine (CIRM) in California (June 26, 2016) and
the Korean National Institutes for Health in Korea (October 19–20, 2016). Through the workshops,
ISCBI is endeavoring to support a new paradigm for human medicine using pluripotent stem cells
(hPSC) for cell therapies. Priority considerations for ISCBI include ensuring the safety and efficacy
of a final cell therapy product and quality assured source materials, such as stem cells and primary
donor cells. To these ends, ISCBI aims to promote global harmonization on quality and safety con-
trol of stem cells for research and the development of starting materials for cell therapies, with
regular workshops involving hPSC banking centers, biologists, and regulatory bodies. Here, we pro-
vide a brief overview of two such recent activities, with summaries of key issues raised. STEM
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SIGNIFICANCE STATEMENT
This article reviews recent discussions among world leading groups working on the provision of
stem cell lines for research and clinical use. It addresses the latest thinking on issues of quality
control, safety, and ethics. A key outcome from the reported workshops was the confirmation
of the need for standards and, in particular, the principles of best practice which have been
developed by the International Stem Cell Banking Initiative.
INTRODUCTION
International Stem Cell Banking Initiative (ISCBI)
was established in 2007 with funding from the
International Stem Cell Forum (http://www.stem-
cell-forum.net/), with the remit to support human
pluripotent stem cells (hPSC) banking centers,
stem cell biologists, regulatory bodies, and others
involved and/or interested in biobanking [1–3].
The ISCBI members have held regular workshops
and have published a series of publications
including best practice for the preparation and
dissemination of hPSCs for research and clinical
application [4, 5]. The ISCBI meetings regularly
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MEETING REPORT
involved delegates from up to 24 countries to reach consensus on
core standards for the field of stem cell research and develop-
ment. In 2016, the ISCBI held a meeting in California (CiRM, 26th
June) and a workshop at the Korean National Institutes for Health
(KNIH) in Korea (19–20 October). In this Report, we provide a
summary of the key points of discussion from both meetings, with
emphasis on data standardization, quality controls for quality
assurance, resource sharing, and the tenet of informed consent.
DATA STANDARDIZATION, PROTECTION
The hPSCreg Project
Prof. Andreas Kurtz (Charite Universit€atsmedizin, Berlin, Germany)
reported on the hPSCreg database funded by the European Com-
mission (EC), which now contained information on about 1,600
hPSC lines from 26 countries. The EC requires registration and cer-
tification of all human embryonic stem cell (hESC) and hiPSC lines
by the registry before they can be used for EC-funded research,
which involves validation of ethical provenance, identity and evi-
dence of pluripotency. A more convenient facility for registering
cell lines in batches is available for cooperation partners. hPSCreg
adopts provisions to protect donor privacy. For instance, certain
cell line’s genetic and clinical data sets, which might be misused to
reidentify anonymized donors, for example, human leukocyte anti-
gen (HLA) and short tandem repeat (STR) profiles, genetic sequen-
ces, are held on the database, but are not released publicly if
open access was not granted by the consenting donor [6]. The
registry makes only two alleles of a STR profile available for public
access, which would enable researchers to initiate independent
confirmation of cell authenticity without releasing full STR pro-
files. Delegates supported the need for a standardized nomencla-
ture for cell naming as published by International Stem Cell
Initiative (ISCI) contributors [7], which also included a recommen-
dation on minimal information to be included in publications of
new hPSC lines. hPSCreg has implemented an automated tool and
register for naming of hPSC lines according to a modification of
the nomenclature standard [8] (https://hpscreg.eu/). It was
acknowledged that day-to-day use of simplified local names was
likely to continue for convenience; but it was felt timely to try to
persuade scientists to use a standard nomenclature for formal
identification, reporting, and referencing of cell lines.
Development of Minimum Information Guidelines for
Stem Cell Data
Prof. Wataru Fujibuchi (Center for iPS Cell Research and Applica-
tion, Kyoto University, Japan) described the MIACARM (Minimum
Information About a Cellular Assay for Regenerative Medicine),
which was published by an international team including Europe,
Japan, and the U.S. in October 2016 [9]. He described the MIA-
CARM data ontogeny which was designed to help standardize cap-
ture of scientific data and processing information applicable to
most stem cell banks and cellular information registries. This was
intended to promote data exchange and facilitation of practical
regenerative medicine. He also outlined the early development of
a standardized ontogeny of cell/tissue descriptors. He indicated
that he was keen to develop and improve the system and
requested feedback on the proposed ontogeny from ISCBI mem-
bers via completion of a “cross-referencing template” and applica-
tion programming interface (API). (http://icscb.stemcellinformatics.
org).
Data Access for Human Induced Pluripotent Stem Cell
(hiPSC) Lines
Laura Clarke (EMBL-EBI, Cambridge, U.K.) described the role of
the European Genome-Phenome Archive [10] in providing access
to biological data via a range of data access arrangements for dif-
ferent cohorts of sample donors. The archive contains sequence,
array, and phenotypic data, with access to data controlled by the
submitter. She also described the HipSci project [10] which had
created 719 induced pluripotent stem cell (iPSC) lines (156 then
available from European Collection of Authenticated Cell Cultures
(ECACC) a member of the EBiSC European iPSC bank project). She
explained the need for care in the management of “unique data”
which she defined as pieces of data which could be used in combi-
nation with other data sets to reidentify an individual. Sequence
data were the prime example of such unique data while proteo-
mics data were considered to be unlikely to facilitate reidentifica-
tion of donors. She also outlined the role of the Global Alliance for
Genomics and Health in providing strategic coordination for the
management of such data sets.
NATIONAL AND INTERNATIONAL STEM CELL BANKING ACTIVITIES
The importance of well-documented quality control and rigorous
traceability for donor materials and the banking process were con-
sistent features in presentations by stem cell banking centers from
Asia, Europe, and North America (see Table 1) who endorsed the
use of international consensus for stem cell banking [5]. In addition,
it was also concluded that retention of original cells used to prepare
iPSC lines was crucial to enable new lines to be developed as iPSC
technology advanced and to provide archival material for testing in
the event of infections or other adverse events in iPSC clinical trials.
Dr. Joanne Mountford (Scottish National Blood Transfusion
Service, Edinburgh, U.K.) described the formation of a global HLA
homozygous haplobank consortium [11] aimed to provide tissue
type matched therapies with reduced risk of immune rejection in
patients. She explained that the development of autologous cell
lines was prohibitively expensive for widespread use but a key regu-
latory challenge also remained to realizing products from a panel of
such lines which was the ability to demonstrate comparability
between products made with different iPSC lines. It was also agreed
that at this point in time it is not clear which reprogramming meth-
ods will prove most satisfactory. Accordingly, it was considered
important to ensure that stocks of cryopreserved donor fibroblast
cultures or primary cells/tissues are retained so that when more
advanced reprogramming techniques are available new iPSC lines
can be derived from the most valuable donor genotypes.
Prof. Tsuneo Takahashi (University of Kyoto, Japan) described
the Japanese Cord Blood Bank Network established in 1998. The
network primarily supported by the Japanese Red Cross had a
program that treated more than 1,000 patients per year using
unrelated cord blood. This was linked with the Japan Marrow
Donor Program (JMDP), which has registered over 400,000
donors. He also described the provision of cord blood units for
research purposes from the Riken BioResource Center in Tsukuba
City. Prof. Takahashi proposed that the basic protocols to produce
clinical grade stem cells should be harmonized and the developing
regulations for regenerative medicine and was convinced that
international guidance, like those of the ISCBI [5], is critical for the
progress of the development of other tissue materials used for
cell therapy and regenerative medicine.
Kim, Kurtz, Yuan et al. 1957
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QUALITY CONTROL FOCUSED ON GENETIC STABILITY TESTING
Characterization of a CIRM-Funded iPSC Resource
Dr. Thomas J. Novak (Cellular Dynamics International, Wisconsin,
U.S.) described Cellular Dynamics International (CDI’s) work to
bank and quality control the 3,000 hPSC lines derived from blood
(80%) and skin (20%) cells using episomal reprogramming, under
sponsorship from CIRM. A total of 1,000 lines deposited at Coriell
had been characterized by a range of methods. A 300,000 SNP
genome array (Illumina’s Infinium HumanCore SNP-Chip) was
used to evaluate genome status which was broadly equivalent in
resolution to G-banding and, in addition, revealed insertion and
deletions (in/dels). SNP-Chip had facilitated high throughput and
low-cost analysis, but this had to be balanced against a compro-
mise on inability to detect inversions and reciprocal transloca-
tions. Differences between karyotype and genome array data had
been observed and the array analysis had missed certain cytoge-
netic changes, but gives some potentially valuable genomic data
on specific sequences affected. Multiple clones from the same
individuals had been generated, but budgetary constraints pre-
vent more than one clone from being analyzed. So far approxi-
mately 20% of lines did not meet the requirements for karyotype
acceptability and Dr. Novak reported that full analysis of the data
would be released in 2018–2019 once it has been analyzed by
awardees of CIRM grants to establish the lines. In the meantime,
individual grant recipients could be approached for the data on
their own lines.
Genetic Stability in Cell Lines in Routine Banking of
hPSC Lines at WiCell
Dr. Tenneille Ludwig (WiCell, U.S.) moderated a discussion on
common recurrent abnormalities seen in human pluripotent stem
cell banking. Group discussion highlighted the apparent trends in
the appearance of abnormalities, including the previously
reported amplicon in chromosome 20 [12]. The discussion
highlighted the prevalence of specific abnormalities across
laboratories globally and underscored the need for testing
strategies and tools to identify these recurrent abnormalities in
routine culture and banking.
Genetic Studies of hESC Banks at the KNIH
Dr. Jung-Hyun Kim (Korea National Stem Cell Bank, KNIH, South
Korea) reported in depth genetic characterization of the first K-
NIH hPSC lines. Data included analysis of copy number variation
(by whole exome sequencing, array comparative genomic hybrid-
ization (aCGH), and array single nucleotide polymorphism (aSNP)),
RNAseq, and epigenetic profiles. Parallel analysis of samples from
premaster, master, and distribution cell banks for each of the six
lines had revealed only one change in karyotype in DNA chromo-
somal analysis between cell banks of the same line.
Comparison of Alternative Methods for the Evaluation
of Genetic Stability in the EBiSC Project
Dr. O’Shea (UK Stem Cell Bank, NIBSC, South Mimms, U.K.)
described a project initiated within the European iPSC bank
(EBiSC) which had performed a comparison of three
techniques for assessment of genome integrity (Geimsa-
banded karyotype, Bacs on Beads [“BoBs”] and arraySNPs)
from common cell line samples. Data to date indicated that
BoBs missed a significant proportion of genetic changes
observed with the other two methods, possibly due to its
lower sensitivity. G-banding had detected some changes not
seen in a SNP analysis but also aSNPs had detected quite large
deletions not seen in karyology. Identical samples of one cell
line sent to three independent cytogenetic laboratories also
showed variation in detailed G-banded karyotype and the
relative proportions of altered clones. The results yet to be
fully completed, raised questions including: what do the
observed changes and variations mean, what level of cells with
abnormal karyotype would classify a cell line as atypical,
should banks be using a combination of techniques, and how
should such genetic stability data be published by stem cell
banks.
QC Test Package Required for iPSC Banks for Clinical
Use Established at the Foundation for Biomedical
Research and Innovation
Prof. Shin Kawamata (Foundation for Biomedical Research and
Innovation [FBRI], Kobe, Japan) introduced the QC test require-
ments for the iPSC-derived product at clinical sites and iPSC clini-
cal banks, based on the experience of the clinical application of
autologous and allogenic iPSC derived retinal pigmented epithe-
lium in Kobe. He mentioned that the iPSC generated by reprog-
ramming should be carefully checked for differentiation capability
because retention of reprogramming factors, genetic damage dur-
ing reprogramming, or the presence of abnormal epigenetic modi-
fication which can render certain differentiation protocols
ineffective. These were considered important in addition to
genetic changes accumulated in the course of long-term culture
of PSC which could generate tumor populations after transplanta-
tion. He proposed distinct QC test sets for iPSC-derived products
at clinical sites. The in vivo transplantation test of the differenti-
ated final product to address tumorigenic and differentiation
potential by examining histology of transplant can also be
included. In addition, a set of simple genetic tests such as karyo-
typing, CGH array can be considered depending on the nature of
the product. The purpose of QC tests at the clinical site is to pro-
vide enough information for a go/no go decision by the clinical
investigator. Therefore, whole genome sequence data in clinical
grade iPSC cell bank without any clinical information may not be
relevant as it is not useful for this kind of decision. He also
addressed the importance of coordination between the iPSC bank
and clinical sites using the iPSCs, to share data on in vivo QC test-
ing of iPSC-derived differentiated cells and QC tests of original
iPSC clones. The QC data sharing system in the community would
also contribute to improve the quality of iPSC clones in the bank
and consequently promote iPSC-derived cell therapy.
The Quality Control (QC) Requirements and Evaluation
of Nonpluripotent Stem Cells
Dr. Bao-Zhu Yuan (NIFDC, Beijing, People’s Republic of China)
introduced a quality control system established by the
National Institutes for Food and Drug Control, an integral part
of China FDA. A key part of this system is the “quality evalua-
tion system,” designed for the evaluation of mesenchymal
stromal cells during preclinical product development. To assure
the quality of the cells to be used in humans in the so-called
“clinical studies,” the cells were expected to meet the quality
requirements of four major categories, which are the general
biological properties, microbiology safety, biology safety, and
biological effectiveness. The process is performed under a
quality management system, which determines the evaluation
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strategies, in which different assessment techniques are com-
bined, according to type, manufacturing process, and clinical
indication of different cells. Another key component was the
quality evaluation technology system, which is a collection of
quality assessment technologies used to evaluate various criti-
cal quality attributes within each category of the major quality
requirements. By applying the evaluation system, several com-
mon quality issues had been identified among the different
products assessed up to the date of the meeting including the
problems associated with cell identity, purity, mycoplasma
contamination, and significant variations in biological activity.
Although the new system had been focused on stem cells, it
was believed that its principles are also applicable to all other
therapeutic cells, including immunotherapeutic cells.
STEM CELL CHARACTERIZATION
A UV-Lithography Surface Patterning Process for Cell
Differentiation
At the 2015 ISCI/ISCBI meeting, Nafees Rahman (University of
Toronto, Canada) had described a 48-hour induced differentiation
assay which used assessment of Oct4/Sox2 expression to dis-
tinguish undifferentiated cells from neuroectoderm, primitive
streak, and extraembryonic differentiated cultures [13]. She
subsequently reported (ISCBI workshop June 2016) a develop-
ment of this assay using UV-lithography for surface patterning.
This development enabled creation of different patterns of
surface treatment shown in the presentation, which could be
used to influence cell differentiation in different ways.
Gastrulation-like differentiation had been modeled using this
system using defined media and was being investigated with a
broader range of cell lines. The assay was being developed to
investigate the effect of bioactive molecules such as kinase
inhibitors. The technology had now developed to the stage
where the treated surfaces could be distributed to other labs
thus facilitating more wider use of this system [14].
New Developments for the Pluritest Assay
Dr. Jeanne Loring (Scripps Research Institute, LaJolla, U.S.)
described the success of uptake of Pluritest, with 727 registered
users in 29 countries and now licensed to Coriell (January
2016). J.L. also reported the unfortunate recent withdrawal of
Pluritest HT12 arrays and potential ways forward including the
development of alternative DNA methylation or RNA analysis
platforms. The preferred option appeared to be the develop-
ment of a new platform based on RNAseq data (see RNA Skim
method [15]). Prof. Loring outlined the options for total RNA or
RNA exome analysis, of which the former was the currently
preferred way forward as it would capture the lnc-RNAs used in
the current Pluritest Platform.
Cell Differentiation on Plastic Microcarriers
Dr. Steve Oh (BTI, ASTAR) reported the development of a
serum-free and chemically defined microcarrier-based suspen-
sion culture platform for scalable hPSC expansion and embry-
onic body (EB) formation. Improved survival and better quality
embryoid bodies with the microcarrier-based method [16]
resulted in significantly improved mesoderm induction and,
when combined with hematopoietic differentiation, resulted
in at least a sixfold improvement in hematopoietic precursor
expansion. This culminated in an 80-fold improvement in the
yield of red blood cells (RBCs) generation compared with a
conventional EB-based differentiation method. In addition, he
reported efficient terminal maturation and generation of
mature enucleated RBCs using a coculture system that com-
prised primary human mesenchymal stromal cells. The
microcarrier-based platform could prove to be an appealing
strategy for future scale-up of hPSC culture, EB generation,
and large-scale generation of RBCs under defined and xeno-
free conditions.
REGULATIONS AND INFORMED CONSENT
A New ISO Standard for Biobanking
Dr. Tohru Masui (Keio University/SKIP, Yokahama, Japan) described
the Stemcell Knowledge and Information Portal being developed
in Japan (SKIP) as an international collaboration. Key challenges
for SKIP included networking a variety of resources and the many
potential identifiers for donors and cell lines. He summarized the
ISO TC276 activity to establish a new international standard for
biobanks and a new research project on its implementation for
Japanese biobanks. ISCBI members perceived problems with the
implementation of a very prescriptive TC276 single standard for
all cell types and fed back constructive comments for a restruc-
tured document. The final international biobank standard
(ISO20387) will be a framework standard for biobanks of
various materials, including human, animal, plant, and micro-
organisms. Where adopted, it will require accreditation by
assessment of competence of each biobank which will have
financial implications, which could impact on research-based
biobanks. However, the quality of biobank resources is crucial
to facilitate effective research and development. Dr. Masui is
coordinating a study group to set minimum criteria for bio-
banks with an achievable and realistic manner. In addition, he
also described the Japanese ethics perspectives for ES cell
research which are based on three principles to derive ES cells
from donated human embryo which are have informed
consent, voluntary donation, and complete anonymization.
With the discovery of iPSC technology using somatic cells,
many people thought that iPSCs avoided some of the ethical
concerns about hESCs. However, it is clear that iPSCs require
the same degree of traceability and anonymity. Accordingly, in
2013, Japan established three regenerative medicine related
acts to address the challenges of these new advanced thera-
pies. It will be tested at authorization and support at develop-
ment of an innovative medical practice with iPSC.
Considerations on Ethics Issues for Use of Pluripotent
Stem Cells
Dr. Geoff Lomax (CIRM, San Francisco, U.S.) summarized the gen-
eral issues of concern at CIRM when establishing model informed
consent procedures for donors of tissues used to create hPSC
lines, which were (a) the potential for commercial development,
(b) sensitive applications (e.g., creation of gametes and embryos,
transplantation into humans), and (c) wide-ranging distribution
and use of cells/derivatives and the associated genetic and medi-
cal information. Useful guidance had been established by the
International Society for Biological and Environmental Resources,
although this was primarily developed from a U.S. perspective.
Key issues for users of hPSC lines were outlined as the impact of
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withdrawal of consent, constraints on freedom to act commer-
cially and constraints or regulation on the freedom to generate
and use genetic data. Withdrawal of consent was an area of spe-
cial concern which had been tackled in different ways in different
jurisdictions. He explained that there had been cases where the
stem cell line had been withdrawn when the donor withdrew
consent and that it is vital to have clarity on whether the with-
drawal of consent affects the cell line or just the original donated
tissue sample. This clearly raised potential future problems that
might be unsolvable once lines had been distributed by banks
and issued clinically. CIRM considered a cut-off of passage 5 up to
which all material could be retracted if consent were withdrawn.
Consenting procedures should be clear on this issue as “silence”
could raise doubts about the utility of lines in academia and
industry. In other jurisdictions, only the original donor tissue
could be withdrawn.
One of the key objectives of ISCBI is the development of
best practices, which includes fostering harmonized or com-
mon approaches for determining sample/hPSC provenance as
well as for developing and evaluating informed consent proc-
esses. Prof. Rosario Isasi (University of Miami, Miller School of
Medicine, U.S.) mentioned ISCBI activities on analyzing policy
convergence for prospective collection/derivation as well as
for the utilization of previously collected specimens for hPSC
derivation, banking, and distribution. There were discussions
centered on identifying commonalities in the adoption of ethi-
cal safeguards to respect donors’ autonomy (i.e., consent) and
privacy interests (i.e., managing genetic data) and to ensure
the ethical integrity of research as well. The ultimate goal is to
ensure conformity with international ethical standards while
respecting moral diversity and sovereignty as reflected in
national regulatory frameworks.
Prof. Glyn Stacey (UKSCB, NIBSC, South Mimms, U.K.)
described new data protection law in the EU which was an area of
some concern to all delegates. The revisions to the EU Directive
on Data Protection and its implementation in EU law could see
significant additional controls on use of raw genetic data from
hPSC lines. This will require screening and monitoring of all access
to raw genetic data to ensure it is not misused and will affect any
exchange of data derived from EU citizens. Such issues and the
need for appropriate best practice for data management in bio-
resource centers were addressed for bio resources centers at a
recent workshop [17].
SUMMARY
In both of the above-mentioned ISCBI meetings, methods for
quality control of genome integrity and stability have been consid-
ered and selection of appropriate assays for this aspect of quality
control are still under investigation. The closely associated Interna-
tional Stem Cell Initiative (http://www.stem-cell-forum.net/) also
organized a workshop on genetic stability (Jackson laboratories,
Bar Harbor, October 2016, contributed to by ISCBI members), also
addressed this issue and will publish its conclusions in 2017. Look-
ing ahead, it will be important to recognize the difference
between research-based characterization of genetic stability and
the need for a cost-effective and standardized quality control
assay for genome integrity in stem cell banks.
From the experiences of at least one of the regulatory
bodies presenting at ISCBI meetings, it is apparent that the mes-
enchymal stromal cell (MSC) field has similar issues relating to
culture stability and the need for screening of appropriate
markers and functional assays. Similar discussions to those out-
lined here for hPSCs are therefore likely to be of benefit in the
banking and control of MSC cultures. A number of groups are
now developing hPSCs for clinical application using the ISCBI
guidance which has also been taken up by banks now supplying
hESCs specifically derived for use in human therapy. However,
the ISCBI banking groups continue to discuss improvement in
quality control for quality assurance, including characterization
of stem cell lines. To this end, ISCBI meetings will continue to
provide a forum for the evaluation of emerging technologies for
culture, characterization, safety testing, and ethical guidelines.
Such iterative processes between expert centers will be impor-
tant in the establishment of safe and effective stocks of stem
cells for future regenerative medicines.
Notwithstanding developments in cell safety and efficacy,
issues for managing ethical aspects of both hESC and iPSC remain
challenging with increasing regulation to be addressed for any
derivatives of human tissues. Standardization in the delivery of
stem cell biobanking and cell therapy products is also progressing,
and those developing and supplying stem cell lines for clinical
application will need to keep abreast of new developments and
emerging issues. It is therefore vital that groups like the ISCBI con-
tinue to stimulate exchange of information on international devel-
opments and review best practice in stem cell banking on a
regular basis. The ISCBI community will continue to provide a
forum for such discussions among key stakeholders including bio-
resource centers, stem cell biologists, regulators, and others with
crucial complementary expertise.
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